KR20150090240A - 결장 종양의 존재 또는 위험의 평가 방법 - Google Patents

결장 종양의 존재 또는 위험의 평가 방법 Download PDF

Info

Publication number
KR20150090240A
KR20150090240A KR1020157017551A KR20157017551A KR20150090240A KR 20150090240 A KR20150090240 A KR 20150090240A KR 1020157017551 A KR1020157017551 A KR 1020157017551A KR 20157017551 A KR20157017551 A KR 20157017551A KR 20150090240 A KR20150090240 A KR 20150090240A
Authority
KR
South Korea
Prior art keywords
leu
ser
glu
ala
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157017551A
Other languages
English (en)
Korean (ko)
Inventor
존 블루메
리안 벤즈
리사 크로너
로슬린 딜런
알로 렌달
제프리 존스
헤더 스코르
톰 스톡피쉬
브루스 윌콕스
다니엘 루더만
Original Assignee
어플라이드 프로테오믹스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어플라이드 프로테오믹스, 인크. filed Critical 어플라이드 프로테오믹스, 인크.
Publication of KR20150090240A publication Critical patent/KR20150090240A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G01N33/57419—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
    • G01N27/62—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosols; by investigating electric discharges, e.g. emission of cathode
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G06F17/27—
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Data Mining & Analysis (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Databases & Information Systems (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Software Systems (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020157017551A 2012-11-30 2013-12-02 결장 종양의 존재 또는 위험의 평가 방법 Withdrawn KR20150090240A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261732024P 2012-11-30 2012-11-30
US61/732,024 2012-11-30
US201361772979P 2013-03-05 2013-03-05
US61/772,979 2013-03-05
PCT/US2013/072691 WO2014085826A2 (en) 2012-11-30 2013-12-02 Method for evaluation of presence of or risk of colon tumors

Publications (1)

Publication Number Publication Date
KR20150090240A true KR20150090240A (ko) 2015-08-05

Family

ID=50828610

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157017551A Withdrawn KR20150090240A (ko) 2012-11-30 2013-12-02 결장 종양의 존재 또는 위험의 평가 방법

Country Status (11)

Country Link
US (6) US20140234854A1 (https=)
EP (1) EP2926138A4 (https=)
JP (1) JP2016507723A (https=)
KR (1) KR20150090240A (https=)
CN (2) CN104969071B (https=)
AU (1) AU2013351947A1 (https=)
BR (1) BR112015012616A2 (https=)
CA (1) CA2893158A1 (https=)
MX (1) MX2015006757A (https=)
SG (1) SG11201504241QA (https=)
WO (1) WO2014085826A2 (https=)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9141756B1 (en) 2010-07-20 2015-09-22 University Of Southern California Multi-scale complex systems transdisciplinary analysis of response to therapy
CN108802385B (zh) 2012-02-09 2022-02-08 米密德诊断学有限公司 用于诊断感染的标记和决定因素和其使用方法
MX2016012697A (es) * 2014-03-28 2017-05-09 Applied Proteomics Inc Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales.
CN106489075B (zh) * 2014-07-11 2019-10-15 爱科谱迅病理研究公司 针对GTP酶KRas蛋白质(KRas)的SRM/MRM测定
BR112017002884A2 (pt) 2014-08-14 2018-01-30 Memed Diagnostics Ltd ?análise computacional de dados biológicos por meio do uso de variedade e hiperplano?
JP2017532699A (ja) * 2014-09-05 2017-11-02 ナントミクス，エルエルシー 起源の判定のためのシステムと方法
CN107209184B (zh) 2014-12-11 2020-04-24 米密德诊断学有限公司 用于诊断多种感染的标记组合及其使用方法
US11513123B2 (en) * 2014-12-11 2022-11-29 Wisconsin Alumni Research Foundation Methods for detection and treatment of colorectal cancer
CN105807062A (zh) * 2014-12-28 2016-07-27 复旦大学 人结肠癌蛋白Spondin-2在制备结肠癌诊断制剂中的应用
CN105385752A (zh) * 2015-03-23 2016-03-09 复旦大学 一种人结肠癌蛋白质标志物Spondin-2的检测方法及其检测试剂盒
WO2016164815A1 (en) * 2015-04-10 2016-10-13 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
JP7002037B2 (ja) * 2015-07-01 2022-02-04 デューク・ユニヴァーシティ 急性呼吸器感染症を診断および処置するための方法
US11047860B2 (en) * 2015-11-05 2021-06-29 Vanderbilt University Protein quantitation in multicellular tissue specimens
EP3423590A4 (en) 2016-03-03 2020-02-26 Memed Diagnostics Ltd. DETERMINANTS OF RNA TO DIFFERENTIATE BACTERIAL VIRAL INFECTIONS
WO2017180652A1 (en) * 2016-04-11 2017-10-19 Applied Proteomics, Inc. Mass spectrometric data analysis workflow
JP6754116B2 (ja) * 2016-04-26 2020-09-09 学校法人近畿大学 大腸癌マーカー
CN107345236A (zh) * 2016-05-04 2017-11-14 北京美泽福临科技发展有限公司 一种amy2b信使rna的特异性扩增引物和肝癌辅助诊断试剂盒
WO2017214625A1 (en) * 2016-06-10 2017-12-14 Wisconsin Alumni Research Foundation Methods for detection, staging, and surveillance of colorectal adenomas and carcinomas
WO2018011796A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
CA3027341A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
CN106202984B (zh) * 2016-08-26 2018-09-04 赵毅 一种基于多层复杂网络对肿瘤miRNA标志物的筛选方法
US11385241B2 (en) 2016-09-29 2022-07-12 Memed Diagnostics Ltd. Methods of prognosis and treatment
WO2018060999A1 (en) * 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
US20180100858A1 (en) * 2016-10-07 2018-04-12 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
JP6813033B2 (ja) * 2017-01-19 2021-01-13 株式会社島津製作所 分析データ解析方法および分析データ解析装置
US11204355B2 (en) 2017-02-20 2021-12-21 Vanderbilt University Immune checkpoint molecular fitness profiling by mass spectrometry
CN106919801B (zh) * 2017-03-08 2023-07-18 杭州大伽信息科技有限公司 一种免疫组织化学染色辅助分析系统及使用方法
CN106908608B (zh) * 2017-04-17 2018-10-02 首都医科大学附属北京胸科医院 辅助诊断重症继发性肺结核的蛋白标志物
US20180330059A1 (en) * 2017-05-09 2018-11-15 James Stewart Bates Patient treatment systems and methods
US10455457B2 (en) 2017-05-24 2019-10-22 Qualcomm Incorporated NR-SS unified operation mode in coordinated and uncoordinated bands
US11164679B2 (en) 2017-06-20 2021-11-02 Advinow, Inc. Systems and methods for intelligent patient interface exam station
US20200124604A1 (en) * 2017-06-30 2020-04-23 National Institutes Of Biomedical Innovation, Health And Nutrition Biomarker for detecting colorectal cancer
CA3069828A1 (en) * 2017-07-14 2019-01-17 Cofactor Genomics, Inc. Immuno-oncology applications using next generation sequencing
CN109406785A (zh) * 2017-08-18 2019-03-01 山东泽济生物科技有限公司 肿瘤血液标志物及其应用
US20200386759A1 (en) * 2017-12-05 2020-12-10 Discerndx, Inc. Robust panels of colorectal cancer biomarkers
CN111699391A (zh) * 2017-12-29 2020-09-22 雅培实验室 用于诊断和评估创伤性脑损伤的新型生物标志物和方法
IL276089B2 (en) * 2018-01-22 2024-07-01 Liquid Biopsy Res Llc Methods for colon cancer detection and treatment monitoring
US11348688B2 (en) 2018-03-06 2022-05-31 Advinow, Inc. Systems and methods for audio medical instrument patient measurements
JP7455757B2 (ja) 2018-04-13 2024-03-26 フリーノーム・ホールディングス・インコーポレイテッド 生体試料の多検体アッセイのための機械学習実装
US20200011871A1 (en) * 2018-07-05 2020-01-09 Edp Biotech Corporation Kits and methods for detecting markers
ES3034592T3 (en) * 2018-08-08 2025-08-20 Regeneron Pharma Use of lc-ms/ms to quantitate protein biomarkers
EP3623813A1 (en) * 2018-09-17 2020-03-18 Institut d'Investigació Sanitària Pere Virgili Methods for the prognosis of hiv-infected subjects
JP7539399B2 (ja) * 2019-03-06 2024-08-23 ディアデム エス．アール．エル． アルツハイマー病の診断と予後判定におけるマーカーとしてのｐ５３ペプチド
WO2021097302A1 (en) * 2019-11-13 2021-05-20 University Of South Florida Systems and methods of deep learning for colorectal polyp screening
CN110951707B (zh) * 2019-12-31 2022-11-11 南京医科大学 丙酮酸激酶m2突变体及其在心血管疾病中的应用
CN115616230A (zh) * 2020-03-18 2023-01-17 龙海市第一医院 用于肝癌早期诊断的检测岩藻糖基化载脂蛋白h的elisa试剂盒
WO2022006628A1 (en) * 2020-07-08 2022-01-13 Southern Adelaide Local Health Network Inc. Computer-implemented method and system for identifying measurable features for use in a predictive model
CN112194719A (zh) * 2020-09-01 2021-01-08 中日友好医院(中日友好临床医学研究所) Crt抗原和mage-a1抗原的制备及其应用
CN112034182A (zh) * 2020-09-01 2020-12-04 复旦大学附属中山医院 一种结肠癌转移预测方法和系统
CN112266961B (zh) * 2020-10-29 2023-05-12 中山大学附属第六医院 Tsg-6基因在预测结直肠癌转移及预后方面的应用
CN112710856B (zh) * 2020-12-16 2022-12-02 江西省肿瘤医院(江西省癌症中心) 检测血清igf1蛋白的制剂在制备结直肠癌疗效监测试剂中的应用
CN114878833B (zh) * 2021-07-01 2026-03-17 浙江大学 一种检测抗过氧化物还原酶-1-IgG抗体的试剂盒
CN113956327B (zh) * 2021-10-11 2024-01-30 中山大学肿瘤防治中心 靶向人apc蛋白的多肽及其在制备药物中的应用
EP4497005A1 (en) * 2022-03-23 2025-01-29 Serum Detect, Inc. Biomarker signatures indicative of early stages of cancer
CN114445406B (zh) * 2022-04-07 2022-08-09 武汉大学 肠镜图像分析方法、装置和医学图像处理设备
TWI796228B (zh) 2022-05-25 2023-03-11 臺中榮民總醫院 急性腎損傷預測系統及其方法
CN114668836B (zh) * 2022-05-27 2022-08-19 暨南大学 Pdia6在制备治疗脊髓损伤和修复的药物中的应用
CN114958794B (zh) * 2022-06-14 2023-06-02 南京工业大学 一种苯乙醇胺-N-甲基转移酶hPNMT54及其克隆表达与应用
CN116593431B (zh) * 2023-04-09 2025-11-07 湖南科技大学三亚研究院 一种基于亲和传感器法的米酵菌酸毒素便携式检测装置及检测方法
US20240379228A1 (en) * 2023-05-08 2024-11-14 Venn Biosciences Corporation Diagnosis of colorectal cancer using targeted quantification of peptides
WO2025058445A1 (ko) * 2023-09-15 2025-03-20 연세대학교 산학협력단 대장암에 대한 정보 제공 방법
CN118067993B (zh) * 2024-04-17 2024-07-05 弗雷米德生物医药技术（天津）有限公司 一种用于肠息肉检测的联检试剂盒及其制备方法、检测方法和应用
CN118496322A (zh) * 2024-05-09 2024-08-16 昆明医科大学 一种靶向降解β-catenin的多肽型抑制剂及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
US4517289A (en) * 1982-08-18 1985-05-14 Brigham And Women's Hospital Monoclonal antibodies for human tissue cross-matching
JP2002515965A (ja) * 1995-08-18 2002-05-28 ダブリュー． ランドリ，ドナルド 抗体触媒反応の調節による有機化合物の検出
US5800347A (en) * 1995-11-03 1998-09-01 The General Hospital Corporation ROC method for early detection of disease
NO954667D0 (no) * 1995-11-17 1995-11-17 Dagfinn Oegreid Fremgangsmåte til deteksjon av Ki-ras mutasjoner
CA2372667A1 (en) * 1999-01-10 2000-11-23 Steven Laken Methods of detecting colorectal disease by conduction an assay to detect a mutation in a bat-26 locus
US20010041365A1 (en) * 2000-01-10 2001-11-15 Michael Laposata Methods for monitoring alcohol consumption
US20040018973A1 (en) * 2002-01-25 2004-01-29 University Of Pittsburgh Nuclear matrix protein alterations associated with colon cancer and colon metastasis to the liver, and uses thereof
US20050153382A1 (en) * 2002-06-06 2005-07-14 Chengdu Kuachang Science And Technology Co., Ltd. Biochip kit comprising biochip based on antigen-antibody reactions, and its usage
JP4912894B2 (ja) * 2004-02-19 2012-04-11 イェール ユニバーシティー プロテオーム技術を使用した癌タンパク質バイオマーカーの同定
WO2006015616A1 (en) * 2004-08-13 2006-02-16 Indivumed Gmbh Use of transthyretin as a biomarker for colorectal adenoma and/or carcinoma; method for detection and test system
US20060105419A1 (en) * 2004-08-16 2006-05-18 Biosite, Inc. Use of a glutathione peroxidase 1 as a marker in cardiovascular conditions
WO2006094149A2 (en) * 2005-03-01 2006-09-08 Exact Sciences Corporation Methods and compositions for detecting adenoma
CN101283280A (zh) * 2005-08-18 2008-10-08 Zadec私人有限公司 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途
EP1946118A4 (en) * 2005-11-10 2009-01-21 Aurelium Biopharma Inc TISSUE DIAGNOSIS OF BREAST CANCER
JP5715817B2 (ja) * 2007-07-19 2015-05-13 ビオメリューＢｉｏｍｅｒｉｅｕｘ 結腸直腸癌のインビトロ診断のための肝臓脂肪酸結合タンパク質、ｃｅａおよびｃａ１９−９のアッセイのための方法
US8426140B2 (en) * 2007-09-28 2013-04-23 Royal College Of Surgeons In Ireland Method of assessing colorectal cancer status in an individual
CN101896817A (zh) * 2007-12-10 2010-11-24 霍夫曼-拉罗奇有限公司 用于结直肠癌的标记物组
CN101896818B (zh) * 2007-12-10 2016-01-20 霍夫曼-拉罗奇有限公司 作为癌症的标记物的Seprase
JP2011511635A (ja) * 2008-02-11 2011-04-14 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド 癌標識としての結腸癌関連転写因子１（ｃｃａｔ−１）
JPWO2009107170A1 (ja) * 2008-02-29 2011-06-30 学校法人日本大学 抗ｃｒｐ抗体及びその利用
US20110245087A1 (en) * 2008-03-18 2011-10-06 Gunter Weiss Method for optimizing and validating an assay for determining the presence or absence of a medical condition
CA2724433A1 (en) * 2008-05-14 2009-11-19 Eth Zuerich Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith
ES2506116T3 (es) * 2008-05-23 2014-10-13 Biocartis Nv Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo
WO2011047358A1 (en) * 2009-10-15 2011-04-21 Crescendo Bioscience Biomarkers and methods for measuring and monitoring inflammatory disease activity
US10119959B2 (en) * 2010-06-25 2018-11-06 The Board Of Trustees Of The Leland Stanford Junior University Method of assaying an individual for immune impairment
WO2012101283A1 (en) * 2011-01-28 2012-08-02 Biosystems International Sas Combinatorial biomarkers for clinical applications in lung cancer patient management
EP2678448A4 (en) * 2011-02-22 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L CIRCULATING BIOMARKERS
WO2013028554A2 (en) * 2011-08-19 2013-02-28 Myriad Genetics, Inc. Gene signatures for lung cancer prognosis and therapy selection

Also Published As

Publication number Publication date
BR112015012616A2 (pt) 2017-09-12
US20140234854A1 (en) 2014-08-21
US20150111230A1 (en) 2015-04-23
US20150111220A1 (en) 2015-04-23
MX2015006757A (es) 2015-11-30
WO2014085826A3 (en) 2014-10-23
WO2014085826A2 (en) 2014-06-05
CN104969071A (zh) 2015-10-07
CN110596385A (zh) 2019-12-20
SG11201504241QA (en) 2015-06-29
US20150111221A1 (en) 2015-04-23
CA2893158A1 (en) 2014-06-05
JP2016507723A (ja) 2016-03-10
US20170285033A1 (en) 2017-10-05
AU2013351947A1 (en) 2015-06-18
CN104969071B (zh) 2019-09-03
US20150111223A1 (en) 2015-04-23
EP2926138A2 (en) 2015-10-07
EP2926138A4 (en) 2016-09-14

Similar Documents

Publication Publication Date Title
CN104969071B (zh) 用于评估结肠肿瘤的存在或风险的方法
US9689874B2 (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
US20170176441A1 (en) Protein biomarker profiles for detecting colorectal tumors
JP6105491B2 (ja) 照合性細胞ベースのアッセイ及びその使用
JP7584486B2 (ja) 乾癬性関節炎の疾患活動性を評価するためのバイオマーカーおよび方法
US20180100858A1 (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
HK1248316A1 (en) Methods of assessing colorectal health of an individual
WO2008064336A9 (en) Autoimmune disease biomarkers
KR20170062453A (ko) 심혈관 위험 사건 예측 및 이의 용도
Albalat et al. Clinical application of urinary proteomics/peptidomics
CA3233138A1 (en) Lung cancer prediction and uses thereof
ES3041461T3 (en) Cardiovascular event risk prediction
US20230048910A1 (en) Methods of Determining Impaired Glucose Tolerance

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000